CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs.

ABSTRACT:

Background

Several drugs are available for the preventive treatment of both episodic and chronic migraine. The choice of which therapy to initiate first, second, or third is not straightforward and is based on multiple factors, including general efficacy, tolerability, potential for serious adverse events, comorbid conditions, and costs. Recently, a new class of migraine preventive drugs was introduced, i.e. monoclonal antibodies against calcitonin gene-related peptide (CGRP) or its receptor.

Methods

The present article summarizes the evidence gathered with this new migraine preventive drug class from randomized placebo-controlled clinical trials. It further puts this into perspective next to the evidence gained by the most widely used agents for the prevention of episodic a

SUBMITTER: Vandervorst F 

PROVIDER: S-EPMC8547103 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature